Healthpeak (DOC) Q1 2026 Earnings Transcript

Healthpeak raised full-year FFO as adjusted guidance to $1.71-$1.75 per share after reporting Q1 FFO as adjusted of $0.45 and reaffirming strong operating momentum. The company completed the Janus Living IPO, retained 81.6% ownership, and expects the transaction to be earnings neutral in 2026 before turning about $0.04 per share accretive in 2027 and beyond. Leasing remained solid across outpatient medical and lab assets, with 1.1 million square feet signed, 91% outpatient occupancy, 77.7% lab occupancy, and at least 100 bps of lab occupancy growth expected by year-end.

Analysis

DOC is signaling a rare REIT setup where operating improvement, capital recycling, and buybacks are all working in the same direction. The important second-order effect is that the market is still likely discounting the stock as a bond proxy, while management is actively shrinking the gap between private-market asset values and public-market earnings power. If they can keep recycling capital into higher-return senior housing and continue buying back stock at a double-digit FFO yield, per-share growth can outpace same-store growth for multiple quarters even if macro rates stay sticky.

The biggest hidden winner is Blackstone, not because of the initial JV economics, but because DOC is effectively validating a repeatable playbook for private capital to crystallize value inside a public REIT platform. That should widen the funnel for similar recap deals across healthcare real estate, and pressure smaller owners with high leverage to accept recap terms rather than wait for a full-cycle recovery. The competitive loser is any lab or outpatient peer that lacks DOC’s scale, relationships, and balance sheet flexibility; those names will likely see more difficult leasing and capital markets conversations as tenants and lenders gravitate toward the perceived “safe harbor” landlords.

The contrarian point is that the market may be underestimating how much earnings can be pulled forward from occupancy inflection in life science. A 100 bp occupancy gain on a sub-80% portfolio has meaningful leverage because the marginal rent lands on largely fixed-cost real estate; that means the next leg of upside is less about face rents and more about absorption. However, the main risk is timing: if 2027 lease-up slips or refinancings stay expensive, the IPO-related dilution and higher interest expense can temporarily mask the operating upside, creating a window for multiple compression even as fundamentals improve.

For the next 3-6 months, the key catalyst stack is continued buybacks, additional Blackstone-style recaps, and visible lab occupancy progress into year-end. If those land, DOC can re-rate on a combination of higher FFO, lower perceived leverage, and better quality-of-earnings optics. If they stall, the stock likely reverts to a yield trade and the upside becomes more muted, but the downside should be buffered by private-market NAV support and ongoing capital returns.

Key Decisions for Investors

• Long DOC on a 3-6 month horizon: best risk/reward is if management executes one or two more recap/buyback actions and lab occupancy keeps trending up; target a re-rating from bond proxy to growth REIT, with downside limited by dividend yield and asset backing.
• Pair trade: long DOC / short a high-beta life science REIT with weaker lease-up visibility and higher refinancing risk over the next 6-12 months; DOC has better self-funded catalysts while weaker peers remain dependent on external capital markets.
• Sell downside hedges on DOC into any post-earnings volatility: the stock has multiple near-term support layers from dividend yield, buyback authorization, and NAV-driven investor interest, making short-dated puts less attractive than owning common.
• Add BX as a satellite long on a 6-12 month view: DOC’s JV template suggests repeat volume in private-capital healthcare real estate, which is a favorable fee/AUM and deployment backdrop for BX.
• Avoid shorting DOC into quarter-end unless lab lease-up deteriorates materially; the asymmetry is poor because capital-return actions can offset modest operating misses, while a positive occupancy print can force a fast multiple expansion.